BG Medicine reports galectin-3 data

BG Medicine Inc. (Waltham, Mass.) reported 6.5 year follow-up data from the DEAL-HF study using the company's BGM Galectin-3 test to aid in the stratification of patients with heart failure. The data showed that plasma levels of galectin-3 were a significant predictor of mortality risk after adjusting for age, gender, severity of chronic heart failure and renal dysfunction (p=0.026). Levels of galectin-3 were also significantly higher in patients who died (n=98) compared with survivors (p=0.01). The prospective, Dutch trial enrolled 232 patients. Data were published in the journal Clinical Research in Cardiology. ...